Gamma Therapeutics, Inc.

Biotech · Defunct

Antisense morpholino oligonucleotides that selectively inhibit gamma prime fibrinogen (GPF) production in liver cells

gamma-therapeutics.com →
Grants
$503K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: Rapid Hemostatic Dressing for Hemorrhage Control$225,000
Federal grantDepartment of Health and Human Services · Phase I · Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels$277,710
Federal grant · SBIR/STTRPress

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1423MOLECULAR THERANOSTICS, LLC——
1424Prime Medicine——
1425Guide Star Biosciences, Inc.—$925K
1426Gamma Therapeutics, Inc.——
1427Solutions BioMed LLC—$5.0M
1428ALVEOLUS BIO, INC.——
1429IMAGINEERING TECHNOLOGIES INC—$14M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Press

2 articles · matched on company name

Patents

USPTO · 0 granted of 1
  • Fast-clotting Wound Dressingsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.